Highest-materiality recent filing
Lisata Therapeutics cuts 72% of workforce, sues Kuva Labs over merger breach
Workforce reduced by ~72% effective immediately; estimated $1.2M in severance costs through Q3 2026.
Lisata Therapeutics terminates merger with Kuva Labs; Kuva failed to secure financing
Merger agreement terminated after Kuva Labs failed to obtain financing to fund tender offer.
Kuva Labs delays tender offer for Lisata to June 10; outside date extended to July 17
Tender offer commencement deadline extended from June 1 to June 10, 2026; company waives claims for previous delay.
Kuva Labs notifies Lisata it will not commence tender offer on June 1 as agreed; deal uncertain
On May 31, Kuva Labs told Lisata it will not start the tender offer on June 1 as previously agreed and amended.
Lisata amends merger: cash per share cut from $5 to $4, CVR increased to up to $3
Cash consideration reduced from $5.00 to $4.00 per share; CVR now offers up to $3.00 total ($1.25 + $1.75 milestone payments).
Lisata extends tender offer deadline to May 29; Kuva to pay up to $1.1M in expenses
Tender offer commencement extended from April 13 to May 29, 2026, under amended merger agreement.
Lisata acquisition in limbo: Kuva Labs delays tender offer, seeks new financing
Kuva Labs has not yet commenced tender offer for Lisata; deadline extended from April 3 to April 13, 2026.
Lisata to be acquired by Kuva Labs for $5.00 per share plus contingent $1.00 CVR
Kuva Labs will acquire all Lisata common shares for $5.00 cash plus one non-tradeable CVR potentially paying $1.00 upon FDA filing for certepetide.
Lisata Therapeutics terminates exclusive license for certepetide with Qilu Pharmaceutical
Mutual termination of 2021 License and Collaboration Agreement with Qilu, effective January 23, 2026.
Lisata to be acquired by Kuva Labs for $4.00 cash/share + up to $2 CVRs; ~85% premium
All-cash tender offer at $4.00/share plus two non-tradeable CVRs worth up to $2/share tied to certepetide milestones.
Lisata reports Q3 2025 net loss $4.2M; cash runway into Q1 2027 with new partnerships
Net loss $4.2M vs $4.9M in Q3 2024; operating expenses down 17% to $4.4M.
Lisata grants Catalent non-exclusive license for certepetide ADC payload; up to $10.5M milestones
Granted Catalent non-exclusive license to use certepetide as ADC payload in SMARTag platform; Catalent assumes all R&D/commercial costs.
Lisata Therapeutics granted US composition-of-matter patent for certepetide expiring 2040
U.S. Patent No. 12,351,653 covers certepetide's chemical structure and pharmacokinetic properties.
Positive Cohort B ASCEND data: 6M PFS 60.8% (certepetide) vs 25% (placebo)
Cohort B: median PFS 7.5 months (certepetide) vs 4.7 months (placebo); ORR 45.2% vs 19%.
Lisata Q1 net loss $4.7M; cash $25.8M; ASCEND Cohort B oral at ESMO-GI Jul 2025
Net loss $4.7M for Q1 2025, vs $5.4M in Q1 2024; operating expenses down 11% to $5.8M.
Revenue $1.0M from Kuva license (vs $0 in 2023); operating expenses down 8.9% to $23.4M.
Lisata reports Phase 2 ASCEND Cohort A: mOS 12.68 vs 9.72 months; 4 complete responses
Cohort A: median OS of 12.68 months for certepetide plus chemo vs 9.72 months for placebo plus chemo.
Lisata Therapeutics Q2 2024 net loss $5.0M; ASCEND Phase 2b top-line data expected Q4 2024
Net loss $5.0M in Q2 2024 vs $4.0M in Q2 2023; operating expenses down 19.7% to $5.5M.
Lisata Q1 net loss $5.4M; ASCEND Phase 2b data on track for Q4 2024
Cash, equivalents and marketable securities $43.3M as of Mar 31, 2024; funding operations into early 2026.
Lisata Q3 net loss $5.3M; ASCEND ~95% enrolled, BOLSTER first patients treated
Net loss of $5.3M in Q3 2023 (vs $37.4M prior year which included $30.4M merger costs); cash $54.4M.
Lisata Q2 net loss $4.0M, extends cash runway to Q1 2026; tech transfer deal for TPN platform
Net loss $4.0M in Q2 2023 vs $6.6M in Q2 2022, down 40% due to $2.2M NJ tax credit.
Lisata Therapeutics reports FY2022 financial results and provides business update
Net loss for FY2022 was $54.2 million, including $30.4 million non-routine merger-related IPR&D expense.
Preliminary unaudited cash, equivalents and marketable securities of ~$69.2M as of Dec 31, 2022.
Lisata Therapeutics Q3 net loss widens to $37.4M on merger costs; cash $75.5M; LSTA1 trials on track
Net loss $37.4M (Q3 2022) vs $6.9M (Q3 2021), driven by merger-related expenses and stock compensation.
Lisata halts XOWNA FREEDOM Trial; development now contingent on partner
Phase 2b FREEDOM Trial of XOWNA (autologous CD34+ cells) suspended May 2022 due to COVID enrollment challenges and heterogeneity.
Lisata Therapeutics formed via Caladrius-Cend merger; ~$76M cash, ticker LSTA
Merger closed 9/15/22: Caladrius issued 0.5338 shares per Cend share after 1:15 reverse split; post-merger shares ~7.82M.
Merger with Cend approved: 25,973,235 for, 2,912,622 against, 172,676 abstain.
Caladrius receives Nasdaq extension to Feb 13, 2023 to regain $1 bid price compliance
Company failed to meet $1 minimum bid price by Aug 17, 2022 initial compliance deadline.
Caladrius Q2 net loss $6.6M; merger with Cend on track for Q3 2022 forming Lisata Therapeutics
Net loss $6.6M vs $5.7M YoY; cash $73M after $10M Cend investment.
Caladrius suspends enrollment in Phase 2b FREEDOM Trial of XOWNA; interim analysis expected Aug 2022
Enrollment paused in 105-patient double-blind placebo-controlled FREEDOM Trial; only ~35 patients enrolled to date.
On April 15, 2024 (the “Effective Date”), the Board of Directors (the “Board”) of Lisata Therapeutics, Inc. (the “Company”) appointed James Nisco as the Company’s Senior Vice President, Finance and Treasury and Chief Accounting Officer, effective immediately.
Lisata Therapeutics, Inc. (the “Company”) today announced that Erkki Ruoslahti, M.D., Ph.D., has decided to retire from its Board of Directors effective today, July 11, 2023.
On May 1, 2023, Lisata Therapeutics, Inc. (the “Company”), after a careful review of capital utilization and prioritization, eliminated the position of President and Chief Business Officer, and terminated the employment of Mr. David Slack, effective immediately.
Mr. Slack has effectively resigned from the Company’s Board of Directors as of May 1, 2023 pursuant to the terms of his Employment Agreement.
Michael H. Davidson, M.D., Steven S. Myers, Peter G. Traber, M.D. and Anne C. Whitaker (the “Departing Directors”) resigned from the Company’s board of directors
Michael H. Davidson, M.D., Steven S. Myers, Peter G. Traber, M.D. and Anne C. Whitaker (the “Departing Directors”) resigned from the Company’s board of directors
Michael H. Davidson, M.D., Steven S. Myers, Peter G. Traber, M.D. and Anne C. Whitaker (the “Departing Directors”) resigned from the Company’s board of directors
Michael H. Davidson, M.D., Steven S. Myers, Peter G. Traber, M.D. and Anne C. Whitaker (the “Departing Directors”) resigned from the Company’s board of directors
appointed David Slack as a member of the Company’s board of directors and as the Company’s President and Chief Business Officer.
On February 24, 2022, Todd C. Girolamo, Esq., Chief Legal Officer, Senior Vice President of Corporate Development and Corporate Secretary of Caladrius Biosciences, Inc. (the “Company”), notified the Company of his intent to resign from all positions held with the Company in order to pursue other career opportunities.
Max materiality 0.90 · Median 0.68 · Most common event other_material